Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -30.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | -30.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding current performance. They highlighted ongoing challenges but maintained a focus on future objectives.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term goals despite short-term setbacks.
The earnings report indicates that Arrowhead Pharmaceuticals is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 2.82%, reflecting investor concerns about the company's current performance and lack of guidance. Without specific revenue figures or future outlook, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SNOWFLAKE INC Class A
Feb 6, 2015